Abstract:Abstract Around 0.75 million babies worldwide suffer from moderate or severe hypoxic-ischemic encephalopathy (HIE) each year resulting in around 400,000 babies with neurodevelopmental impairment. In 2010, neonatal HIE was associated with 2.4% of the total Global Burden of Disease. Therapeutic hypothermia (TH), a treatment that is now standard of care in high-income countries, provides proof of concept that strategies that aim to improve neurodevelopment are not only possible but can also be implemented to clinical practice. While TH is beneficial, neonates with moderate or severe HIE treated with TH still experience devastating complications: 48% (range: 44–53) combined death or moderate/severe disability. There is a concern that TH may not be effective in low- and middle-income countries. Therapies that further improve outcomes are desperately needed, and in high-income countries, they must be tested in conjunction with TH. We have in this review focussed on pharmacological treatment options (e.g. erythropoietin, allopurinol, melatonin, cannabidiol, exendin-4/exenatide). Erythropoietin and allopurinol show promise and are progressing towards the clinic with ongoing definitive phase 3 randomised placebo-controlled trials. However, there remain global challenges for the next decade. Conclusion : There is a need for more optimal animal models, greater industry support/sponsorship, increased use of juvenile toxicology, dose-ranging studies with pharmacokinetic-pharmacodynamic modelling, and well-designed clinical trials to avoid exposure to harmful medications or abandoning putative treatments. What is Known: • Therapeutic hypothermia is beneficial in neonatal hypoxic-ischemic encephalopathy. • Neonates with moderate or severe hypoxic-ischemic encephalopathy treated with therapeutic hypothermia still experience severe sequelae. What is New: • Erythropoietin, allopurinol, melatonin, cannabidiol, and exendin-4/exenatide show promise in conjunction with therapeutic hypothermia. • There is a need for more optimal animal models, greater industry support/sponsorship, increased use of juvenile toxicology, dose-ranging studies with pharmacokinetic-pharmacodynamic modelling, and well-designed clinical trials.

Neuroprotective Effects of Diabetes Drugs for the Treatment of Neonatal Hypoxia-Ischemia Encephalopathy

Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy

New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy

Pyruvate administered to newborn rats with insulin-induced hypoglycemic brain injury reduces neuronal death and cognitive impairment

Repetitive and profound insulin-induced hypoglycemia results in brain damage in newborn rats: an approach to establish an animal model of brain injury induced by neonatal hypoglycemia

Emerging therapeutic strategies in hypoxic-ischemic encephalopathy: a focus on cognitive outcomes

Neuroprotective strategies for neonatal hypoxic-ischemic brain damage: Current status and challenges

Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy

Neuroprotective strategies following perinatal hypoxia-ischemia: Taking aim at NOS

Neonatal Hypoxia Ischaemia: Mechanisms, Models, and Therapeutic Challenges

Nutraceuticals in the Prevention of Neonatal Hypoxia–Ischemia: A Comprehensive Review of their Neuroprotective Properties, Mechanisms of Action and Future Directions

Targeting the Multiple Complex Processes of Hypoxia-Ischemia to Achieve Neuroprotection

Pharmacological Neuroprotection of the Preterm Brain: Current Evidence and Perspectives

Neonatal encephalopathy due to suspected hypoxic ischemic encephalopathy: pathophysiology, current, and emerging treatments

Erythropoietin for neonatal brain injury: opportunity and challenge

Stem Cell Therapy for Neonatal Hypoxic-Ischemic Encephalopathy: A Systematic Review of Preclinical Studies

Hypoglycemia and hyperglycemia in neonatal encephalopathy: A narrative review

Neonatal dysglycemia: a review of dysglycemia in relation to brain health and neurodevelopmental outcomes

Preventing Brain Injury in the Preterm Infant—Current Controversies and Potential Therapies

[Clinical Evidence for the Pharmacological Therapy in Newborn Infants with Hypoxic-Ischemic Encephalopathy].

Effects of DHEA and DHEAS in Neonatal Hypoxic–Ischemic Brain Injury